More on MIST

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-83.3% Growth)
- Ratings (8.9 Score)

Upcoming Events

- Earnings (11/17/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Milestone Pharmaceuticals Inc. (NQ:MIST)
Delayed: 0.79 --0 (-0%)
Prev. Close $0.79  
Open$0.79 
52 Wk High$ 
52 Wk Low$ 
Day High$0.79 
Day Low$0.79 
P/E N/A  
EPS$ 
Volume481 

Friends, Peers and Foes (?): ATR, ACOG, CBAY, ONCT, ALNY (more...)

Sep 24, 2026 08:01 AM Milestone Pharmaceuticals enrolls first Canadian patient in AFib trial
Sep 24, 2026 08:00 AM Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
Sep 4, 2026 06:46 AM H.C. Wainwright Reiterates Buy Rating on Milestone Pharmaceuticals (MIST)
Aug 27, 2026 08:01 AM Milestone study finds PSVT impacts patient life between episodes
Aug 27, 2026 08:00 AM Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes
Aug 21, 2026 08:00 AM Milestone Pharmaceuticals starts Phase 3 AFib-RVR trial for etripamil
Aug 21, 2026 08:00 AM Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
Aug 20, 2026 06:08 AM Cantor Fitzgerald Starts Milestone Pharmaceuticals (MIST) at Overweight
Aug 12, 2026 07:29 AM Form 8-K Milestone Pharmaceutical For: Aug 12
Aug 12, 2026 07:16 AM Milestone Pharmaceuticals Inc. (MIST) Misses Q2 EPS by 2c
View All Articles

Entities mentioned with MIST

View All Entities